Skip to main content
Premium Trial:

Request an Annual Quote

Bostwick Labs to Market MDxHealth's Prostate Cancer Test

NEW YORK (GenomeWeb News) – MDxHealth and Bostwick Laboratories today announced a marketing agreement covering MDxHealth's ConfirmMDx prostate cancer test.

The deal, they said, provides MDxHealth with access to one of the largest urology networks in the US. Bostwick specializes in anatomic and clinical pathology.

Financial and other terms of the deal were not disclosed.

"With their national reach and strong reputation, Bostwick Laboratories is an ideal partner to help us continue building upon the momentum we have achieved to date, raising awareness and access to ConfirmMDx within the urology community," MDxHealth CEO Jan Groen said in a statement.

ConfirmMDx helps clinicians differentiate patients with true negative biopsies from those at risk for occult cancer. MDxHealth received approval from the State of New York for ConfirmMDx earlier this month, making the epigenetics-based test available in all 50 states in the US.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.